Helen Tayton-Martin

Company: Adaptimmune Therapeutics plc.

Job title: Chief Business Officer

Seminars:

Round table: Endurance Unveiled: TCR Therapies Showcasing Durability in Solid Tumors 3:00 pm

Discuss key clinical trials highlighting the enduring efficacy of TCR therapies in solid tumors, emphasizing long-term patient responses and sustained anti-tumor effects Explore the underlying mechanisms contributing to the durability of TCR therapies in solid tumors, delving into factors influencing persistence and resistance patterns Engage patients and experts to discuss lived experiences and future expectations…Read more

day: DAY ONE TRACK 3 B